BRAINBox Solutions Advances TBI Diagnostic Program with New Research and Collaborations

BRAINBox Solutions Advances TBI Diagnostic Program

BRAINBox Solutions, a leader in trauma-related diagnostics, recently announced major updates regarding its clinical and developmental progress in their TBI (Traumatic Brain Injury) diagnostic and prognostic tests. On March 30, 2026, during the 16th Annual TBI Conference in Philadelphia, BRAINBox's CEO Donna Edmonds shared insightful details about their breakthroughs in identifying concussion types and managing care for affected patients.

The company's flagship initiative, the BRAINBox TBI test, aims to bridge a crucial gap in clinical practice by offering an objective standard to identify mild traumatic brain injury (mTBI) patients and assess those at risk for enduring symptoms. The innovative program is designed to cater to a wide range of age groups and is applicable in both point-of-care (PoC) settings and laboratory environments.

Key Updates in Clinical Trials

Among the pivotal developments, BRAINBox recently presented its comprehensive findings from the HeadSMART II clinical trial, aimed at adult populations. This trial is nearing completion, having evaluated over 2,000 samples and is crucial for securing regulatory approval from the U.S. Food and Drug Administration (FDA) to facilitate marketing clearance. Additionally, significant updates were shared on a National Institutes of Health (NIH)-sponsored clinical trial investigating the BRAINBox test's efficacy in geriatric patients.

The presentation from Dr. W. Franklin Peacock, the Principal Investigator and Professor of Emergency Medicine, highlighted the trial's aim to refine precision strategies for TBI detection and management, showcasing the importance of this work for public health.

Collaboration with Prolight Diagnostics

An exciting partnership is on the horizon as BRAINBox entered a collaboration with Prolight Diagnostics, a prominent player in the PoC technology landscape. Initial results from their collaboration have shown encouraging performance by the Psyros™ single-molecule platform when integrating biomarkers crucial for detecting brain injuries. Thus far, the collaboration is moving toward the next phase, which involves a comprehensive evaluation using samples from the HeadSMART II trial, an essential step moving forward in the diagnostic process.

Utilizing Machine Learning for Diagnosis

Additionally, BRAINBox is leveraging advanced machine learning algorithms to enhance its testing frameworks, particularly for elderly patients. Presentations at notable conferences, including